Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press120210.17650/1726-9776-2005-1-3-51-54DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORSДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫTumor markers during screening and monitoring of patients with cancer of the urinary bladderОпухолевые маркеры при скрининге и мониторинге больных раком мочевого пузыряDarenkovS. P.ДаренковС. П.
Russian Federation
PerlinD. V.ПерлинД. В.
Russian Federation
ParshinaV. N.ПаршинаВ. Н.
Russian Federation
ChernyshevI. V.ЧернышевИ. В.
Russian Federation
НИИ урологии Минздрава РФПоликлиника № 5 ФСБ РФ, Москва300920051351541902202019022020https://oncourology.abvpress.ru/oncur/article/view/1202

The study was undertaken to evaluate the specificity and sensitivity of a rapid method for qualitative determination of the content of NMP 22 in the diagnosis of cancer of the bladder, as well as the efficiency of the method in detecting recurrences of this disease.

The method is based on enzyme immunoassay of the nuclear matrix proteins that are incorporated into the cell nuclear membrane, whose levels are approximately 20—80 times higher in the cancer cells of the bladder. The study included 83 patients. Group 1 comprised 18 patients with new-onset bladder cancer. Group 2 comprised 26 patients with histologically verified recurrent bladder cancer. Group 3 consisted of 19 patients who had a history of bladder cancer, received surgical treatment, and had no recurrences for at least 6 months. The control group included 20 healthy donors.

The test urine was put into a test well and the results were assessed 30 minutes later.

The resultant sensitivity of the test was 50% (p < 0.05) in the patients with new-onset cancer of the bladder and 54% (p < 0.05) in those with its recurrent cancer. With staging and grading of the disease and with higher tumor anaplasia, the sensitivity of the test increases: 37, 75, and 80% in T1, T2, T3, respectively (p < 0.05); 30, 50, and 87% in G1 (p > 0.05), G2 (p < 0.05), G3 (p < 0.05). Its specificity was 100% in Group 3 and 90% in the control group (p < 0.05). Thus, its total specificity was 95% (p < 0.05). The study has led to the conclusion that detection of NMP 22 is a promising marker of bladder carcinoma, which show a rather high specificity and specificity not only in identifying primary tumors, but a recurrence of the disease.

.

1. Давыдов М.И., Аксель Е.М. Злокачественные образования в России и странах СНГ в 2001 г. — М., 2003.Давыдов М.И., Аксель Е.М. Злокачественные образования в России и странах СНГ в 2001 г. — М., 2003.2. Клиническая онкоурология / Под ред. Б.П.Матвеева.— М., 2003. — С.197—225.Клиническая онкоурология / Под ред. Б.П.Матвеева.— М., 2003. — С.197—225.3. Sensitivity and specificity: paper by A.Saad et al. // B. J. U. International. — 2002. — Vol. 89(4). March. — Р. 369—373.Sensitivity and specificity: paper by A.Saad et al. // B. J. U. International. — 2002. — Vol. 89(4). March. — Р. 369—373.4. Poulakis V., Witzsch U., De Vries R. et al. А comparison of urinary nuclear matrix protein — 22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results // ВJU International. — 2001. —88. — 692—701.Poulakis V., Witzsch U., De Vries R. et al. А comparison of urinary nuclear matrix protein — 22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results // ВJU International. — 2001. —88. — 692—701.5. Сергеева Н.С., Маршутина Н.В. Новые серологические и уринологические опухолевые маркеры в уточняющей диагностике и мониторинге онкологических больных: Материалы VII Российского онкологического конгресса.Сергеева Н.С., Маршутина Н.В. Новые серологические и уринологические опухолевые маркеры в уточняющей диагностике и мониторинге онкологических больных: Материалы VII Российского онкологического конгресса.6. Lee E. Ponsky, Shashikala Narma, Lakshimi Pandrangi et al. Screening and monitoring for bladder cancer: refining the use of NMP 22 // J. Urol. — July, 2001. — Vol.166; 75—78.Lee E. Ponsky, Shashikala Narma, Lakshimi Pandrangi et al. Screening and monitoring for bladder cancer: refining the use of NMP 22 // J. Urol. — July, 2001. — Vol.166; 75—78.7. Del Nero Al., Esposito N., Curro A. et al. Evaluation of Urinary Level of NMP 22 as a Diagnostic Marker for Stage pTa-pT1 Bladder Cancer: Comparison with Urinary Cytology and BTA Test // Eur. Urology. — 1999; 35; 93—97.Del Nero Al., Esposito N., Curro A. et al. Evaluation of Urinary Level of NMP 22 as a Diagnostic Marker for Stage pTa-pT1 Bladder Cancer: Comparison with Urinary Cytology and BTA Test // Eur. Urology. — 1999; 35; 93—97.8. Steiner G., Schoenberg M.P., Linn J.F. Detection of bladder cancer recurrence by microsatellite analysis of urine // Nat. Med. — 1997; 3: 621.Steiner G., Schoenberg M.P., Linn J.F. Detection of bladder cancer recurrence by microsatellite analysis of urine // Nat. Med. — 1997; 3: 621.9. Sharma S., Zippe C., Pandrangi L. et al. Exclusion Criteria Enhance the Specificity and Positive Predictive Value of NMP 22 and BTA STAT // J. Urol. — July, 1999:162; 53—57.Sharma S., Zippe C., Pandrangi L. et al. Exclusion Criteria Enhance the Specificity and Positive Predictive Value of NMP 22 and BTA STAT // J. Urol. — July, 1999:162; 53—57.10. Akaza H., Miyanaga N. et al. Evaluation of Urinary NMP 22 (Nuclear Matrix Protein 22) as a Diagnostic Marker for Urothelial Cancer — Screening for Urothelial Cancer in Patients with Microscopic Hematuria // Jpn. J. Cancer Chemotherapy. — 1997; 24 (7): 837—842.Akaza H., Miyanaga N. et al. Evaluation of Urinary NMP 22 (Nuclear Matrix Protein 22) as a Diagnostic Marker for Urothelial Cancer — Screening for Urothelial Cancer in Patients with Microscopic Hematuria // Jpn. J. Cancer Chemotherapy. — 1997; 24 (7): 837—842.11. Stampfer D.A., Campinito G.A., Rodriguez-Villanueva J. et al. Evaluation of NMP 22 in the Detection of Transitional Cell Carcinoma of the Bladder // J. Urol. — February, 1998; 158: 1899—1901.Stampfer D.A., Campinito G.A., Rodriguez-Villanueva J. et al. Evaluation of NMP 22 in the Detection of Transitional Cell Carcinoma of the Bladder // J. Urol. — February, 1998; 158: 1899—1901.12. landman J., Kavaler E., Chang Y. et al. Sensitivity and Specificity of NMP 22, Telomerase, and BTA in the Detection of Human Bladder Cancer. — New York, NY (Presented by Dr. Landman) // J. Urol. — June, 1998; 159: 47—52.landman J., Kavaler E., Chang Y. et al. Sensitivity and Specificity of NMP 22, Telomerase, and BTA in the Detection of Human Bladder Cancer. — New York, NY (Presented by Dr. Landman) // J. Urol. — June, 1998; 159: 47—52.13. Landman J., Droller M.J. and B. C-S. Liu et al. Evaluation of Urinary Nuclear Matrix Protein (NMP 22) as a Potential Screening Marker for Transitional Cell Carcinoma of the Urinary Tract. — Mt. Sinai Medical Center, New York, NY. The Sixth European Urological Winter Forum, Davos, Switzerland. — February 16—21, 1997.Landman J., Droller M.J. and B. C-S. Liu et al. Evaluation of Urinary Nuclear Matrix Protein (NMP 22) as a Potential Screening Marker for Transitional Cell Carcinoma of the Urinary Tract. — Mt. Sinai Medical Center, New York, NY. The Sixth European Urological Winter Forum, Davos, Switzerland. — February 16—21, 1997.14. Landman J., Chang Y., Kavalier E. et al. Sensitivity and Specificity of NMP 22, Telomerase, and BTA in the Detection of Human Bladder Cancer // Urology. — Sentember, 1998; 52(3): 398—402.Landman J., Chang Y., Kavalier E. et al. Sensitivity and Specificity of NMP 22, Telomerase, and BTA in the Detection of Human Bladder Cancer // Urology. — Sentember, 1998; 52(3): 398—402.